摘要
目的探讨miR-193a-3p靶向Sox5对结直肠癌干细胞增殖、迁移和侵袭的影响和机制。方法结直肠癌干细胞分成对照组(常规培养)、第1转染组(转染mimics control)、第2转染组(转染miR-193a-3p mimics)、第3转染组(转染pcDNA3.1-Sox5、miR-193a-3p mimics)和第4转染组(转染pcDNA3.1、miR-193a-3p mimic)。用噻唑蓝(MTT)检测各组细胞增殖情况,Transwell小室检测各组细胞侵袭和迁移情况。结果对照组、第1转染组、第2转染组、第3转染组、第4转染组细胞存活率分别为(100.00±9.65)%,(96.68±12.54)%,(47.06±3.21)%,(65.88±3.24)%,(47.06±4.53)%;细胞侵袭数目分别为(68.24±4.12),(67.93±5.07),(29.81±3.55),(55.12±3.26),(30.25±2.74)个;细胞迁移数目分别为(92.14±6.81),(90.68±8.72),(51.04±4.30),(76.24±6.07),(50.87±6.39)个。以上指标,第2转染组和第1转染组比较,第4转染组和第3转染组比较,差异均有统计学意义(均P<0.05)。结论miR-193a-3p靶向Sox5抑制结直肠癌干细胞增殖、迁移和侵袭。
Objective To investigate the effect and mechanism of miR-193 a-3 p targeting Sox5 on proliferation,migration and invasion of colorectal cancer stem cells.Methods Colorectal cancer stem cells were divided into control group(routine treatment),transfection-1 group(transfected with mimics control),transfection-2 group(transfected with miR-193 a-3 p mimics),transfection-3 group(transfected with miR-193 a-3 p mimics,pcDNA3.1-Sox5)and transfection-4 group(transfected with miR-193 a-3 p mimics,pcDNA3.1).Cell proliferation was detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT),cell invasion and migration were detected by Transwell method.Results The cell survival rates of the control group,transfection-1 group,transfection-2 group,transfection-3 group,transfection-4 group were(100.00±9.65)%and(96.68±12.54)%,(47.06±3.21)%,(65.88±3.24)%,(47.06±4.53)%,respectively;the number of cell invasions were 68.24±4.12,67.93±5.07,29.81±3.55,55.12±3.26,30.25±2.74,respectively;the cell migration numbers were 92.14±6.81,90.68±8.72,51.04±4.30,76.24±6.07,50.87±6.39.There were statistically significant differences in the above indices between the transfection-2 group and transfection-1 group,and between transfection-4 group and transfection-3 group(all P<0.05).Conclusion miR-193 a-3 p targeting Sox5 inhibits the proliferation,migration and invasion of colorectal cancer stem cells.
作者
钟轩
蒋涛
朱彤
王红钰
ZHONG Xuan;JIANG Tao;ZHU Tong;WANG Hong-yu(Department of General Surgery,Kailuan General Hospital,Tangshan 063000,Hebei Province,China;Department of Emergency,Kailuan General Hospital,Tangshan 063000,Hebei Province,China;Department of Oncology,Affiliated Hospital of Chengde Medical College,Chengde 067000,Hebei Province,China;Department of Oncology,Tangshan Workers Hospital,Tangshan 063000,Hebei Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第18期2832-2834,共3页
The Chinese Journal of Clinical Pharmacology
基金
河北省卫生厅重点科技研究计划基金资助项目(20191341)。